Table 1.

Summary of papers that have identified SVs in human cells

Cell category	Cell line(s) or type(s)	Genotoxicity type	References
Cancer cell lines	HEK293(T), K562, COLO320, SW1463, HCC2998, HTC116, HAP1, Hep2G	Chromosomal truncations, translocations, kilobase and megabase deletions, insertions, complex insertions and deletions	(Boutin et al. 2021; Cullot et al. 2019; Geng et al. 2022; Liu et al. 2021; Przewrocka et al. 2020; Rayner et al. 2019; Xin et al. 2022; Yin et al. 2019, 2022; Yoo et al. 2022; Zhang et al. 2021)
Primary cells	hTERT-fibroblasts, hTERT-RPE1	Kilobase deletions, insertions and rearrangements, chromosomal truncations, micro-nucleation and chromothripsis	(Cullot et al. 2019; Kosicki et al. 2018; Leibowitz et al. 2021)
	Fibroblasts	Kilobase and megabase deletions, complex insertions and deletions, micro-nucleation	(Cullot et al. 2019; Leibowitz et al. 2021)
	T-cells	Kilobase deletions, copy-neutral loss of heterozygosity, translocations	(Wen et al. 2021; Yin et al. 2022)
	iPSCs	Kilobase deletions, copy-neutral loss of heterozygosity, insertions	(Simkin et al. 2022; Weisheit et al. 2020; Wen et al. 2021)
	HSPCs	Kilobase deletions, insertions, copy-neutral loss of heterozygosity, translocations, micro-nucleation	(Boutin et al. 2021; Leibowitz et al. 2021; Turchiano et al. 2021; Wen et al. 2021)
Embryonic cells	ESCs	Kilobase and megabase deletions, chromosome loss, copy-neutral loss of heterozygosity	(Bi et al. 2020)
	Zygotes/Embryos	Kilobase deletions, truncations, copy-neutral loss of heterozygosity, chromosome loss	(Alanis-Lobato et al. 2021; Zuccaro et al. 2020)